The Zhitong Finance App learned that on November 9, Hong Kong's Financial Secretary Chan Mao-po said that the next stage in the development of surgical robots should focus on expanding popularity to benefit more doctors and patients; Hong Kong will support the growth of innovative medical enterprises and explore the international market through financing, regulatory reform, cross-border clinical research and talent development.
Hong Kong's innovative surgical robot company Connolston held the first Future Surgery Forum today. In his speech, Chen Maobo said that Hong Kong Investment Management Co., Ltd. provides patient capital, while the biotech company listing system allows companies still in the R&D stage to raise capital from global investors. He pointed out that since the reform of the listing system in 2018, more than 90 related companies have been listed in Hong Kong, including surgical robot companies, making Hong Kong the second largest biotech fund-raising center in the world.
On the regulatory side, Chan Mao-po said that the Hong Kong Drug and Medical Device Supervision and Administration Centre will be established within this year to further establish Hong Kong's ability to independently evaluate drugs and medical devices. Through the Hong Kong and Macau Pharmaceutical Connect, 100 medical devices already used in Hong Kong have been approved for use by 71 designated medical institutions in the Greater Bay Area.
The CEO of Hong Kong Investment Corporation, Chen Jiaqi, emphasized in his speech that as an early supporter of Connolston, Hong Kong Investment Corporation deployed patient capital to connect international capital and industrial partners. From a startup company born and raised in Hong Kong, it has become one of the world's top surgical robot brands, confirming the successful practice of a business model based in Hong Kong, backed by the Greater Bay Area and the country, and facing the international community. She said that it will continue to transform capital into development effectiveness, so that innovative results can benefit more patients around the world.